Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2016) 128 (22): 976.

https://doi.org/10.1182/blood.V128.22.976.976

Published: 2016

Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD

Blood (2015) 126 (23): 3029.

https://doi.org/10.1182/blood.V126.23.3029.3029

Published: 2015

Journal Articles

Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide

Hua Jiang, MDPhD, Chirag Acharya, MD, Gang An Gang An, MDPhD, Xiaoyan Feng, MD, Zhili Song, Guang Yang, PhD, Francisco Adrian, Lugui Qiu, MD, Paul Richardson, MD, Nikhil C. Munshi, MD, Yu-Tzu Tai, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 4253.

https://doi.org/10.1182/blood.V126.23.4253.4253

Published: 2015

Journal Articles

Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant

Nancy A. Kernan, MD, Stephan A. Grupp, MD PhD, Kamalika Banerjee, MS, Alison L. Hannah, MD, Robin L. Hume, MS, Bijan Nejadnik, MD, Paul Richardson, MD

Blood (2015) 126 (23): 4330.

https://doi.org/10.1182/blood.V126.23.4330.4330

Published: 2015

Journal Articles

The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells

Deepika Sharma Das, PhD, Arghya Ray, PhD, Yan Song, PhD, Paul Richardson, MD, Bryan Oronsky, Jan Scicinski, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 918.

https://doi.org/10.1182/blood.V126.23.918.918

Published: 2015

Journal Articles

Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma

Deepika Sharma Das, PhD, Yan Song, PhD, Arghya Ray, PhD, Paul Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 1813.

https://doi.org/10.1182/blood.V126.23.1813.1813

Published: 2015

Journal Articles

Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo

Deepika Sharma Das, PhD, Arghya Ray, PhD, Yan Song, PhD, Paul Richardson, MD, Mohit Trikha, PhD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 1821.

https://doi.org/10.1182/blood.V126.23.1821.1821

Published: 2015

Journal Articles

Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia

Jana Jakubikova, PhD, Danka Cholujova, PhD, Teru Hideshima, MD PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Steven P. Treon, MD PhD, Paul Richardson, MD, Efstathios Kastritis, MD, David M Dorfman, MD PhD, Kenneth C. Anderson, MD PhD

Blood (2014) 124 (21): 2070.

https://doi.org/10.1182/blood.V124.21.2070.2070

Published: 2014

Journal Articles

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

Jana Jakubikova, PhD, Efstathios Kastritis, MD, Danka Cholujova, PhD, Teru Hideshima, MD PhD, Ludmila M Flores, Merav Leiba, MD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul Richardson, MD, David M Dorfman, MD PhD, Kenneth C. Anderson, MD PhD

Blood (2014) 124 (21): 3404.

https://doi.org/10.1182/blood.V124.21.3404.3404

Published: 2014

Journal Articles

A Novel Small Molecule Inhibitor Of Deubiquitylating Enzyme USP14 and UCHL5 Induces Apoptosis In Myeloma Cells and Overcomes Bortezomib Resistance

Ze Tian, Ph.D, Padraig D'Arcy, Ph.D, Xin Wang, Ph.D, Arghya Ray, Yu-Tzu Tai, PhD, Yiguo Hu, PhD, Ruben Carrasco, MD, PhD, Deepika Das, Ph.D, Paul Richardson, MD, Stig Linder, MD, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1923.

https://doi.org/10.1182/blood.V122.21.1923.1923

Published: 2013

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

Journal Articles

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

Rao H Prabhala, PH.D., Mariateresa Fulciniti, PhD, Dheeraj Pelluru, PhD, Puru Nanjappa, MS, Christine Pai, BS, Saem Lee, B.A., Nithya Prabhala, Weihua Song, MD, Constantine S. Mitsiades, MD, PhD, Konstantinos Lefkimmiatis, PhD, Yu-Tzu Tai, PhD, Irene Ghobrial, MD, Paul Richardson, MD, John Daley, Kenneth C. Anderson, MD, Seth Ettenberg, Franco Di Padova, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 456.

https://doi.org/10.1182/blood.V116.21.456.456

Published: 2010

Journal Articles

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Paul Richardson, MD, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Meletios A. Dimopoulos, MD, Jean-Luc Harousseau, MD, Jennifer Houp, Thorsten Graef, MD, PhD, Christine K Gause, Catriona Byrne, Kenneth C. Anderson, MD, David Siegel, MD, PhD

Blood (2010) 116 (21): 1951.

https://doi.org/10.1182/blood.V116.21.1951.1951

Published: 2010

Journal Articles

A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.

Gullu Gorgun, PhD, Elisabetta Calabrese, MD, Teru Hideshima, MD, PhD, Jeffrey Ecsedy, PhD, Giada Bianchi, MD, Mala Mani, PhD, Madhavi Bandi, Hiroshi Ikeda, MD, PhD, Giulia Perrone, MD, Yiguo Hu, MD, PhD, Yu-Tzu Tai, PhD, Mei Zheng, Diana Cristea, MD, Loredana Santo, MD, Daniel R. Carrasco, MD, PhD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3830.

https://doi.org/10.1182/blood.V114.22.3830.3830

Published: 2009

Journal Articles

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

Gullu Gorgun, PhD, Elisabetta Calabrese, MD, Teru Hideshima, MD, PhD, Giulia Perrone, MD, Giada Bianchi, MD, Hiroshi Ikeda, MD, PhD, Mala Mani, PhD, Yiguo Hu, MD, PhD, Diana Cristea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 950.

https://doi.org/10.1182/blood.V114.22.950.950

Published: 2009

Journal Articles

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

David Siegel, Donna M Weber, MD, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Syed Rizvi, Jason Howe, David Reiser, Catriona Byrne, Kenneth C. Anderson, MD, Paul Richardson, MD, PhD

Blood (2009) 114 (22): 305.

https://doi.org/10.1182/blood.V114.22.305.305

Published: 2009

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

Journal Articles

Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma

Blood (2008) 112 (11): 826.

https://doi.org/10.1182/blood.V112.11.826.826

Published: 2008

Journal Articles

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Blood (2008) 112 (11): 870.

https://doi.org/10.1182/blood.V112.11.870.870

Published: 2008

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

NARROW

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide

Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant

The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells

Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma

Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo

Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

A Novel Small Molecule Inhibitor Of Deubiquitylating Enzyme USP14 and UCHL5 Induces Apoptosis In Myeloma Cells and Overcomes Bortezomib Resistance

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only